r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial

Official Title

Phase I, Open Label, Randomised Three-way Cross Over, Single-centre Trial to Assess the Bioequivalence for Two Concentrations of the New r-hGH Liquid Multidose Formulation Versus the r-hGH Freeze-dried Multidose Formulation Administered in Healthy Volunteers

Brief Summary

      The primary objective of the trial was to assess the bioequivalence for two concentrations
      (5.83 mg/mL and 8 mg/mL) of the new r-hGH liquid multidose formulation using the r hGH
      freeze-dried multidose formulation (Saizen® 8 mg, 8.8 mg/1.51 mL) as reference.

      Each volunteer received three r hGH treatments, with each treatment being administered as a
      single subcutaneous dose of 4 mg r-hGH in a randomized sequence with at least one week of
      wash-out period between successive treatments.

Study Phase

Phase 1

Study Type


Primary Outcome

Primary endpoints were the pharmacokinetic (PK) parameters of r-hGH: the area under the serum concentration-time curve from time zero to last detectable serum concentration (AUC0 t) and the maximum observed serum concentration (Cmax).

Secondary Outcome

 Secondary endpoints included further PK parameters.


Growth Failure


r-hGH liquid (Saizen)

Study Arms / Comparison Groups

 Arm A


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 2008

Primary Completion Date

August 2008

Eligibility Criteria

        Inclusion Criteria:

        Main inclusion criteria:

          1. Male and female aged 18 to 45 years, inclusive; who are able to read, to write and to
             fully understand German language

          2. Had given written Informed Consent

          3. Had a body weight greater than 55 kg and a body mass index (BMI) of >20 and < or = 30
             kg/m2 (BMI = weight (kg)/height (m)2)

          4. Had vital signs in the following normal range:

             Ear body temperature: 35.0 - 38.0°C

             Blood pressure (BP) - after at least 3 minutes of rest, measured in the supine

             systolic blood pressure: 90 - 145 mmHg diastolic blood pressure : 50 - 95 mmHg Pulse
             rate (PR): after at least 3 minutes of rest, measured in the supine position: 40 90

          5. Smoked less than 10 cigarettes per day, consented to smoke less than 5 cigarettes per
             day during the trial period and were able to refrain from smoking during the
             confinement period

          6. Were able to communicate well with the Investigator and willing to comply with the
             requirements of the entire trial

          7. Were willing to undergo pituitary down-regulation by intravenous infusion with
             somatostatin for 25 hours

             If female:

          8. Had a negative serum pregnancy test within three weeks prior to trial start and a
             negative urine pregnancy test at the day before dosing

          9. Were pre-menopausal and using an adequate method of non-hormonal contraception (2
             barrier methods, or one barrier method with spermicide, or non-hormonal intrauterine
             device), sexual abstinence or females with vasectomised partners during the entire

        Exclusion Criteria:

        Main exclusion criteria:

          1. Any surgical or medical condition, including findings in the medical history or in the
             pre trial assessments, that in the opinion of the Investigator, constituted a risk or
             a contraindication for the participation of the subject in the trial or that could
             have interfered with the trial objectives, conduct or evaluation

          2. Had any clinically significant abnormal laboratory test results in the pre-trial
             safety laboratory tests or any clinically abnormal findings on the 12 leads resting
             electrocardiogram (ECG) that in the opinion of the Investigator may have increased the
             safety risk to the subject

          3. Had positive results for drugs of abuse or alcohol test

          4. Had positive results from serology examination for Hepatitis B surface antigen (HBsAg)
             (not due to vaccination), Hepatitis B core antibody (HBcAb) (if positive, was to be
             verified by test for anti-Hbc-IgM), Hepatitis C Virus (anti-HCV) and Human
             Immunodeficiency Virus (anti-HIV 1 and 2) at screening

          5. History or presence of hypertension or other significant cardiovascular abnormalities

          6. History or presence of cholelithiasis

          7. Significant history or clinical evidence of auto-immune, gastrointestinal,
             haematological, hematopoietic, hepatic, neurological, pancreatic or renal disease

          8. History or presence of diabetes

          9. History or presence of tumors of the pituitary gland or hypothalamus

         10. Definite or suspected personal history or family history of adverse drug reaction or
             hypersensitivity to drugs with a similar chemical structure to somatropin or
             somatostatin or its excipients, use of any chronic medication




18 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Michael Lissy, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

EMD Serono

Study Sponsor

Michael Lissy, MD, Principal Investigator, AAIPharma Deutschland GmbH & Co. KG

Verification Date

October 2013